What was the overall market valuation of the GCC hematopoietic stem-cell-transplantation market in 2024?

The overall market valuation was $117.7 Million in 2024. Read More

What is the projected market valuation for the GCC hematopoietic stem-cell-transplantation market by 2035?

The projected valuation for 2035 is $407.69 Million. Read More

Which companies are considered key players in the GCC hematopoietic stem-cell-transplantation market?

Key players include Novartis, Bristol-Myers Squibb, Amgen, Gilead Sciences, Celgene, Takeda Pharmaceutical, Roche, Merck & Co., and AstraZeneca. Read More

What are the market segments for transplant types in the GCC hematopoietic stem-cell-transplantation market?

The market segments for transplant types include Allogeneic ($250.0 Million) and Autologous ($157.69 Million). Read More

What are the leading indications for hematopoietic stem-cell transplantation in the GCC market?

Leading indications include Acute Myeloid Leukemia ($108.0 Million) and Acute Lymphoblastic Leukemia ($70.0 Million). Read More

What applications are included in the GCC hematopoietic stem-cell-transplantation market?

Applications include Bone Marrow Transplant ($140.0 Million) and Peripheral Blood Stem Cells Transplant ($180.0 Million). Read More

How does the market for Non-Hodgkin Lymphoma compare to other indications in the GCC market?

The market for Non-Hodgkin Lymphoma is valued at $90.0 Million, indicating a strong position among other indications. Read More

What is the valuation range for Cord Blood Transplant in the GCC market?

The valuation range for Cord Blood Transplant is between $27.7 Million and $87.69 Million. Read More

GCC Hematopoietic Stem Cell Transplantation Market

Q: What is the expected CAGR for the GCC hematopoietic stem-cell-transplantation market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 11.96%. Read More

Q: What does the growth trajectory of the GCC hematopoietic stem-cell-transplantation market suggest for future investments?

The growth trajectory suggests a robust opportunity for investments, particularly with a projected valuation increase to $407.69 Million by 2035. Read More

ID: MRFR/LS/48281-HCR

200 Pages

Satyendra Maurya

Last Updated: April 24, 2026

GCC Hematopoietic Stem Cell Transplantation Market Research Report By Transplant Type (Allogeneic, Autologous), By Indication (Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Other Non-Malignant Disorders) and By Application (Bone Marrow Transplant, Peripheral Blood Stem Cells Transplant, Cord Blood Transplant) - Growth & Industry Forecast 2025 To 2035

GCC Hematopoietic Stem Cell Transplantation Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Transplant Type (USD Million)
  1. 4.1.1 Allogeneic
  2. 4.1.2 Autologous
2. 4.2 Life Sciences, BY Indication (USD Million)
  1. 4.2.1 Acute Myeloid Leukemia
  2. 4.2.2 Acute Lymphoblastic Leukemia
  3. 4.2.3 Hodgkin Lymphoma
  4. 4.2.4 Non-Hodgkin Lymphoma
  5. 4.2.5 Multiple Myeloma
  6. 4.2.6 Other Non-Malignant Disorders
3. 4.3 Life Sciences, BY Application (USD Million)
  1. 4.3.1 Bone Marrow Transplant
  2. 4.3.2 Peripheral Blood Stem Cells Transplant
  3. 4.3.3 Cord Blood Transplant
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bristol-Myers Squibb (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Amgen (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Gilead Sciences (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Celgene (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Takeda Pharmaceutical (JP)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Roche (CH)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Merck & Co. (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 AstraZeneca (GB)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 GCC MARKET ANALYSIS BY TRANSPLANT TYPE
3. 6.3 GCC MARKET ANALYSIS BY INDICATION
4. 6.4 GCC MARKET ANALYSIS BY APPLICATION
5. 6.5 KEY BUYING CRITERIA OF LIFE SCIENCES
6. 6.6 RESEARCH PROCESS OF MRFR
7. 6.7 DRO ANALYSIS OF LIFE SCIENCES
8. 6.8 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
9. 6.9 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 SUPPLY / VALUE CHAIN: LIFE SCIENCES
11. 6.11 LIFE SCIENCES, BY TRANSPLANT TYPE, 2024 (% SHARE)
12. 6.12 LIFE SCIENCES, BY TRANSPLANT TYPE, 2024 TO 2035 (USD Million)
13. 6.13 LIFE SCIENCES, BY INDICATION, 2024 (% SHARE)
14. 6.14 LIFE SCIENCES, BY INDICATION, 2024 TO 2035 (USD Million)
15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
16. 6.16 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TRANSPLANT TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY INDICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

GCC Life Sciences Market Segmentation

Life Sciences By Transplant Type (USD Million, 2025-2035)

Allogeneic
Autologous

Life Sciences By Indication (USD Million, 2025-2035)

Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Multiple Myeloma
Other Non-Malignant Disorders

Life Sciences By Application (USD Million, 2025-2035)

Bone Marrow Transplant
Peripheral Blood Stem Cells Transplant
Cord Blood Transplant

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”